Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02887053
Other study ID # 2008-A01209-46
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 2008
Est. completion date May 26, 2022

Study information

Verified date July 2022
Source Central Hospital, Nancy, France
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to optimize clinical MR protocols and to validate MR acquisition parameters.


Recruitment information / eligibility

Status Completed
Enrollment 1807
Est. completion date May 26, 2022
Est. primary completion date May 26, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - to be over 18 year-old, - to be able to give an informed consent, - to have underwent a pre-inclusion medical examination, - to present no contraindication to MR examination, - to be enrolled in a social security plan. Exclusion Criteria: - subject refusal, - subject under a measure of legal protection, - any contraindication to MR examination (active medical device, ferromagnetic foreign body, pregnancy, morbid obesity, claustrophobia, … ).

Study Design


Related Conditions & MeSH terms


Intervention

Device:
MRI


Locations

Country Name City State
France CHRU de Nancy Nancy

Sponsors (1)

Lead Sponsor Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Image quality based on standard imaging quality criteria Image quality criteria will be :
Signal to Noise Ratio and Contrast to Noise Ratio measured in arbitrary units.
absence of blurring and artefacts will be assessed by at least one radiologist according to an ordinal scale
6 months after the last inclusion
Secondary T1/T2 Quantitative sub studies For quantitative studies such as T1/T2 studies a T1/T2 quantification will be calculated. These parameters will be reported in ms. 6 months after the last inclusion
Secondary Brain Functional MRI sub studies For functional MRI studies, brain activity will be described in terms of brain localisation based on blood oxygen level-dependent signal variation and its intensity. 6 months after the last inclusion
Secondary Cardiac function MRI sub studies: volume For cardiac imaging, cardiac function will be evaluated. Parameters such as left ventricle (LV) and right ventricle (RV) end-diastolic volumes end-systolic volumes will be measured and reported in mL/m². 6 months after the last inclusion
Secondary Cardiac mass MRI sub studies: mass For cardiac imaging, cardiac function will be evaluated. LV and RV mass index will be measured and reported in g/m2. 6 months after the last inclusion
Secondary Cardiac function MRI sub studies: ejection fraction For cardiac imaging, cardiac function will be evaluated. Ejection fraction for both ventricles will be calculated and reported in %. 6 months after the last inclusion
Secondary Diffusion weighted MRI sub studies For diffusion studies, the apparent diffusion coefficient (ADC) whic is a measure of the magnitude of diffusion (of water molecules) within tissue will be estimated (mm2/s). 6 months after the last inclusion
Secondary Diffusion tensor MRI sub studies The fractional anisotropy (FA) which is a scalar value between zero and one, which describes the degree of anisotropy of a diffusion process, could also be estimated. 6 months after the last inclusion
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1